Dipartimento di Farmacia, Sezione di Chimica del Farmaco e del Prodotto Cosmetico, Università degli Studi di Genova, Viale Benedetto XV 3, I-16132 Genova, Italy.
Bioorg Med Chem. 2013 Nov 1;21(21):6328-36. doi: 10.1016/j.bmc.2013.08.056. Epub 2013 Sep 6.
Pyrimidopyrimidine derivatives 1 were prepared as rigid thioanalogues of merbarone (a catalytic topoisomerase II inhibitor) and screened as antiproliferative agents against different tumor cell lines. A number of the synthesized compounds emerged as cytotoxic in cell-based assays (MT-4, HeLa and MCF-7 cells) at low micromolar concentrations. In a National Cancer Institute screening, selected member of the series showed a broad spectrum of antiproliferative activity against various tumours (melanoma, renal, CNS, colon and breast cancers). The acid-base and steric properties of the substituent at position 7 of the pyrimidopyrimidine scaffold deeply affected potency. Enzymatic assays evidenced that a subset of tested derivatives efficiently inhibit topoisomerase IIα accordingly to merbarone mechanism of action. However this property does not fully rationalize the cytotoxicity data of the full ligand panel, suggesting that different target(s) should be additionally involved.
嘧啶并嘧啶衍生物 1 被制备为 merbarone(一种催化拓扑异构酶 II 抑制剂)的刚性硫类似物,并被筛选为针对不同肿瘤细胞系的抗增殖剂。许多合成的化合物在基于细胞的测定中(MT-4、HeLa 和 MCF-7 细胞)以低微摩尔浓度表现出细胞毒性。在国家癌症研究所的筛选中,该系列的选定成员对各种肿瘤(黑色素瘤、肾、中枢神经系统、结肠和乳腺癌)表现出广谱的增殖活性。嘧啶并嘧啶支架 7 位取代基的酸碱和空间性质对效力有很大影响。酶促测定表明,一部分测试的衍生物根据 merbarone 的作用机制有效地抑制拓扑异构酶 IIα。然而,该性质不能完全解释整个配体组的细胞毒性数据,表明应该另外涉及不同的靶标。